Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benwel
- Development stage
- Unknown
- Lead developer
- Epione Pharmaceuticals
- Administration
- Oral
01
Overview
**Benwel** is an oral, film-coated multi-ingredient nutraceutical product developed by Epione for joint health and symptomatic support in osteoarthritis. Each tablet contains rosehip extract, Boswellia serrata extract, devil's claw extract, glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane. Epione describes the product as intended to support cartilage protection, reduce joint pain and stiffness, and improve joint flexibility and mobility; its ingredient rationale includes anti-inflammatory and cartilage-supporting effects. ([epionepharma.com](https://epionepharma.com/pdf/Benwel.pdf))
- Brand names
- Benwel
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)
Beyond the preview
Go deeper on Benwel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benwel.